Diphenhydramine
Viewing r1 — Apr 24, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Diphenhydramine is a synthetic depressant and deliriant of the ethanolamine antihistamine class. It is the active ingredient in Benadryl, one of the most widely sold allergy and sleep medications worldwide. It blocks histamine and acetylcholine signaling in the brain, producing sedation at low doses and full delirium at high ones.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
George Rieveschl synthesized diphenhydramine in 1943, and it became the first FDA-approved antihistamine three years later.[1] Moving to over-the-counter status in 1985 made it one of the most accessible sedatives worldwide and one of the most commonly misused antihistamines. Rising overdoses and fatalities — including deaths linked to social media challenges — have since prompted multiple countries to restrict access.
Subjective effects include sedation, dry mouth, impaired coordination, and — at high doses — vivid hallucinations, disorientation, and memory blackout. The high-dose experience is defined by a complete loss of reality testing — hallucinations feel indistinguishable from real life, and the state is overwhelmingly dysphoric. Anxiety, confusion, rapid heart rate, and an inability to recognize the experience as drug-induced are characteristic unsought effects.
Diphenhydramine produces both physical and psychological dependence with chronic use,[2] and the margin between a therapeutic and a fatal dose is narrow.[3][4] Tolerance to sedation drives dose escalation; overdose disrupts heart rhythm through two independent mechanisms,[5] and chronic use is linked to higher dementia risk.[6] Eight decades of therapeutic research exist, but the deliriant experience has never been studied under controlled conditions.
History[edit]
Discovery
Diphenhydramine was synthesized by George Rieveschl in 1943 and licensed to Parke-Davis, who marketed it as Benadryl.[1][7] It became the first antihistamine approved for prescription use in the United States in 1946.[1]
Therapeutic expansion
The drug's utility expanded quickly. A patient on diphenhydramine for hives noticed improvement in motion sickness — leading to dimenhydrinate, a diphenhydramine salt now used as an antiemetic.[7] Moving to over-the-counter status in 1985 dramatically expanded both access and the potential for misuse.[8][9]
Regulatory response
Rising adverse events — including deaths linked to social media overdose challenges[10] — have driven regulatory tightening in multiple countries. A nine-year forensic review documented 25 diphenhydramine-only deaths, with 20 of 25 certified as suicides.[4] Australia reclassified it as prescription-only effective July 2026;[11] Germany, the Netherlands, and Sweden already require a prescription.[9]
The trade name Benadryl became so synonymous with diphenhydramine that many users do not recognize the generic name. In online drug communities, it occupies a singular position as one of the only widely discussed deliriants — and trip reports are strongly cautionary in a way uncommon for other substances. The "Benadryl Challenge" — a social media phenomenon encouraging supratherapeutic doses — drew national attention after multiple pediatric hospitalizations and at least one death.[10]
Chemistry[edit]
Diphenhydramine is an ethanolamine antihistamine — a class built on a short two-carbon backbone with two phenyl rings attached via an ether linkage.[12] Its molecular formula is C₁₇H₂₁NO (255.35 g/mol).
It is highly fat-soluble, crossing readily from the bloodstream into the brain — which is why it produces stronger central nervous system effects than second-generation antihistamines.[12] Dimenhydrinate, a salt of diphenhydramine, is used separately as an antiemetic for motion sickness.[7]
Pharmacology[edit]
Mechanism of action
Diphenhydramine suppresses histamine H1 receptors in the brain.[12][13][14][15] Rather than simply blocking histamine from binding, it actively reduces the receptor's baseline activity — a property called inverse agonism. This suppresses the brain's arousal system, producing sedation, reduced attention, and psychomotor slowing.
At higher doses, the drug also blocks acetylcholine receptors across the brain and body.[16][12][17] This causes dry mouth, tachycardia, and urinary retention at therapeutic doses. At supratherapeutic doses it disrupts the circuits that separate real perceptions from internally generated ones — producing the hallucinations and delirium that define its deliriant profile.
Pharmacokinetics
Taken orally, diphenhydramine peaks in the bloodstream within 1.5–2.5 hours[18][19][13] and clears in 4–6 hours in healthy adults — longer if the liver is impaired.[20] It inhibits a liver enzyme (CYP2D6) that processes other medications,[17] raising blood levels of drugs like beta-blockers and reducing the effectiveness of codeine.
Neuroscience[edit]
Where it acts
Diphenhydramine's sedative effects come from blocking histamine-releasing neurons that drive the brain's arousal system, reducing the signals that keep the cortex alert.[12] At supratherapeutic doses, blocking acetylcholine circuits in the cortex and hippocampus disrupts the brain's ability to separate real perceptions from internally generated ones — the mechanism underlying anticholinergic delirium.[21][22]
Why it matters
Even a single therapeutic dose impairs memory. A controlled study found that 100 mg of diphenhydramine produces memory deficits comparable to 1.5 mg of lorazepam.[23] Repeated long-term use suppresses acetylcholine activity in memory-critical brain regions; large population studies consistently link high anticholinergic drug exposure to increased dementia risk,[6] though whether this is causal remains debated.
No neuroimaging study has examined brain activity during diphenhydramine-induced delirium. The relative contribution of blocking acetylcholine versus blocking glutamate signaling[24] to the deliriant experience has not been experimentally separated.[12] The neural signature of anticholinergic hallucinations remains entirely unmapped.
Subjective Effects[edit]
At therapeutic doses, diphenhydramine is sedative — sedation, thought deceleration, and mild cognitive dulling. At supratherapeutic doses the character changes completely: hallucinations emerge that are indistinguishable from reality, conversations happen with people who are not present, and the boundary between imagination and perception collapses. The state is overwhelmingly dysphoric and cannot be steered.
Compared to DXM, diphenhydramine produces less dissociation and more anticholinergic toxicity. Compared to scopolamine, it requires much higher doses to reach delirium but produces a similar hallucinatory profile once there. Unlike classical psychedelics, set and setting offer almost no modulation — the anticholinergic delirium arrives regardless of context.
Effect Grid
At common doses (75–150 mg oral), sedation intensifies significantly and is accompanied by pronounced psychomotor impairment — impaired digit symbol substitution, slowed choice reaction time, and degraded sustained attention. Memory impairment becomes notable, with prompted recall at 100 mg comparable to lorazepam 1.5 mg. Anticholinergic effects are more pronounced: persistent dry mouth, blurred vision, urinary retention, and constipation.
Physically, tachycardia becomes more consistent. Mild mydriasis may be detectable. Body heaviness and motor incoordination increase.
This range exceeds recommended OTC dosing. Interaction with alcohol or benzodiazepines at these doses significantly amplifies impairment. Sleep is typically induced within 30–60 minutes, but quality may be poor with fragmented architecture.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual haze / noise · Auditory distortion · Auditory misinterpretation · Dreaming suppression · Light sensitivity · Spatial disorientation · Vestibular distortion · Visual drifting · Dreaming enhancement · Auditory enhancement · Depth perception distortion · Auditory suppression · Touch suppression · Music enhancement · Perspective distortion · Proprioceptive distortion · Touch enhancement · Shadow people · External hallucinations · Auditory hallucinations · Visual processing suppression · Object transformations · Object activation · Internal hallucinations · Gustatory hallucination · Olfactory hallucination · Perspective hallucinations
Light sensitivity · Spatial disorientation · Vestibular distortion · Visual drifting · Dreaming enhancement · Auditory enhancement · Depth perception distortion · Auditory suppression · Touch suppression · Music enhancement · Perspective distortion · Proprioceptive distortion · Touch enhancement · Shadow people · External hallucinations · Auditory hallucinations · Visual processing suppression · Object transformations · Object activation · Internal hallucinations · Gustatory hallucination · Olfactory hallucination · Perspective hallucinations
Pupil dilation · Dehydration sensation · Dizziness · Bodily heaviness · Constipation · Sexual arousal suppression · Nausea · Abnormal heartbeat · Headache · Appetite suppression · Involuntary body movements · Spontaneous body sensations · Restlessness · Body high · Muscle relaxation · Muscle tension · Respiratory depression · Body schema distortion · Nystagmus (eye wobbles) · Tingling / electric sensations · Trembling · Vomiting · Wakefulness · Bruxism · Stimulation · Tactile hallucination · Bodily dissociation
Bodily heaviness · Constipation · Sexual arousal suppression · Nausea · Headache · Appetite suppression · Involuntary body movements · Spontaneous body sensations · Restlessness · Body high · Muscle relaxation · Muscle tension · Respiratory depression · Body schema distortion · Nystagmus (eye wobbles) · Tingling / electric sensations · Trembling · Vomiting · Wakefulness · Bruxism · Stimulation · Tactile hallucination · Bodily dissociation
Cognitive fatigue · Thought deceleration · Memory suppression · Cognitive dysphoria · Confusion · Information processing suppression · Pattern recognition suppression · Language suppression · Motivation suppression · Thought disorganization · Creativity suppression · Memory fragmentation · Aesthetic suppression · Suggestibility enhancement · Thought loops · Compulsive redosing urge · Amnesia · Delirium · Delusions
Cognitive dysphoria · Confusion · Information processing suppression · Pattern recognition suppression · Language suppression · Motivation suppression · Thought disorganization · Creativity suppression · Memory fragmentation · Aesthetic suppression · Thought loops · Compulsive redosing urge · Amnesia · Delirium · Delusions
Irritability · Emotional lability · Anhedonia · Empathy suppression · Euphoria
Euphoria
Derealization · Disinhibition · Depersonalization · Emotional susceptibility · Cognitive disconnection · Identity alteration
Cognitive disconnection · Identity alteration
Timeline
First perceptible effects: a gentle wave of drowsiness and faint dry-mouth sensation. At therapeutic doses, onset may be barely noticed; at high doses, early restlessness or unease may emerge.
Sedation deepens progressively. Dry mouth, blurred vision, and motor heaviness become clearly noticeable. At supratherapeutic doses, cognitive clouding and mild confusion begin.
Maximum sedation and anticholinergic effects. At therapeutic doses, deep drowsiness and psychomotor impairment. At deliriant doses, full anticholinergic delirium with formed hallucinations, severe cognitive disorganization, tachycardia, and mydriasis.
Effects remain substantial but begin a slow decline. Sedation persists, anticholinergic symptoms (dry mouth, urinary retention) may remain at peak severity. At deliriant doses, hallucinations may become intermittent but confusion continues.
Gradual return toward baseline. Drowsiness persists but cognitive clarity begins to recover. Anticholinergic symptoms slowly resolve.
Residual grogginess, dry mouth, and mild cognitive dulling may persist for 6–12 hours or into the following day. Sleep architecture may be disrupted despite initial sleep promotion.
⚠ Do not drive or operate machinery until at least 12 hours after dosing, or longer if residual drowsiness persists.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- High
- Withdrawal
- Mild
- Tolerance buildup
- rapid
- Tolerance reset
- —
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- —
Toxicity
Acute toxicity
The gap between a safe dose and a dangerous one is narrow. Hallucinations and agitation appear around 300 mg; seizures, cardiac arrhythmia, and respiratory failure occur above 1,000 mg.[3] Fatalities generally involve amounts approaching or exceeding 2 g.
A nine-year forensic review found 25 diphenhydramine-only deaths — 20 of 25 certified as suicides.[4] Pediatric surveillance (2008–2015) documented over 2,000 adverse events and five deaths.[22] A 2023 case report described a 14-year-old's death from a social media overdose challenge, with postmortem blood levels approximately 500 times the therapeutic range.[10]
Heart and circulation
Overdose disrupts heart rhythm through two independent mechanisms. Sodium channel blockade widens the electrical conduction signal (QRS widening) and can trigger a dangerous rapid heartbeat.[5][25] Potassium channel blockade prolongs the QT interval and can produce a rapidly twisting, potentially fatal rhythm called torsade de pointes.[3]
Standard dialysis does not work because diphenhydramine distributes deeply into body tissues.[3] Hospital treatment targets the cardiac effects directly: sodium bicarbonate for conduction abnormalities,[26] intravenous lipid emulsion for collapse,[27] and ECMO for refractory cardiac arrest.[28]
Anticholinergic syndrome
The classic presentation — described as "hot, dry, red, mad" — includes fever, dry skin, flushing, rapid heart rate, dilated pupils, inability to urinate, and delirium. Physostigmine, a drug that boosts acetylcholine levels, reverses the syndrome and is associated with fewer intubations and ICU admissions compared to supportive care alone.[29][30]
Chronic toxicity
Cumulative anticholinergic exposure is associated with increased dementia risk in large population studies.[6] Diphenhydramine carries a high per-dose anticholinergic load, making chronic use a particular concern in older adults. The American Academy of Sleep Medicine recommends against its use for chronic insomnia.[31]
Psychological Risks
At supratherapeutic doses, the primary risk is a state of severe cognitive disorganization — vivid visual, auditory, and tactile hallucinations that are indistinguishable from reality.[21][22] Unlike psychedelics, the deliriant state is consistently dysphoric — dominated by fear and confusion, with no insight that the experience is drug-induced.
Hallucinations appear in nearly half of pediatric adverse events;[22] community reports consistently describe characteristic "shadow people" visions. Agitation accompanies delirium in approximately one-third of cases.[22] At therapeutic doses (25–100 mg), effects are limited to sedation, mild memory suppression, and reduced attention.[23]
Tolerance & Dependence
Tolerance to sedation develops rapidly with repeated daily use,[31][20] driving dose escalation. Antihistaminic effects also diminish with continued use. Dependence — both physical and psychological — develops with chronic use,[2] and stopping after prolonged use produces rebound effect insomnia, anxiety, and irritability.[2]
Drug Interactions
CNS depressants: Diphenhydramine significantly amplifies the sedation and impairment from alcohol and benzodiazepines.[32] Combined with opioids, sedative-hypnotics, or antipsychotics, the risk of respiratory depression compounds.[13]
Anticholinergic agents: Combining diphenhydramine with tricyclic antidepressants, antipsychotics, or other first-generation antihistamines stacks anticholinergic burden — increasing the risk of delirium, urinary retention, bowel obstruction, and dangerous overheating.[13]
MAOIs: An interaction concern noted in clinical references due to potential additive CNS and anticholinergic effects. No controlled study data quantify this interaction.safety citation needed
CYP2D6 substrates: Diphenhydramine raises blood levels of drugs processed by the CYP2D6 enzyme — including beta-blockers like metoprolol and propranolol — and may reduce the effectiveness of codeine and tramadol by blocking their conversion to active form.[17]
Contraindications
Absolute:
- Neonates and premature infants — risk of fatal respiratory depression[13]
- Breastfeeding — excreted in breast milk and may sedate the infant[13]
- Narrow-angle glaucoma — pupil dilation can trigger an acute pressure crisis in the eye[13]
Relative:
- Enlarged prostate — risk of acute urinary retention[13]
- Liver impairment — half-life extends to 9–15 hours, increasing drug accumulation[20]
- Elderly patients — high anticholinergic burden, falls risk, and cognitive effects; listed in Beers Criteria as potentially inappropriatecitation needed
- Children under 2 years — regulatory agencies recommend against usecitation needed
- Restless legs syndrome — antihistamines can worsen symptoms[33]
Harm Reduction[edit]
Forms & Identification
Diphenhydramine is widely available in tablets, capsules, liquid gels, and liquid formulations — almost always as the hydrochloride salt. Because it is a mass-produced pharmaceutical, the primary risks are not adulteration but dose miscounting (especially with liquid formulations) and combination products containing additional active ingredients such as acetaminophen, pseudoephedrine, or phenylephrine.
Always verify any product used contains diphenhydramine as the sole active ingredient. Combination products introduce independent overdose risks — acetaminophen in particular causes irreversible liver damage at high doses.
Guidelines
- Verify the product contains diphenhydramine as the sole active ingredient — combination products with acetaminophen, ibuprofen, or decongestants introduce separate, potentially fatal toxicity risks
- Start at the lowest effective dose for any intended purpose; the gap between sedating and deliriant is narrower than most users expect
- Do not combine with alcohol, benzodiazepines, opioids, or other sedating substances — the respiratory and cardiac depression stacks
- Do not combine with other anticholinergic medications (tricyclic antidepressants, antipsychotics, other first-generation antihistamines) — the delirium risk compounds
- If using for sleep, limit to occasional short-term use; tolerance to sedation develops within days, and dose escalation follows
- Hydrate — anticholinergic effects suppress sweating and impair temperature regulation
- Do not drive or operate machinery after taking any dose
Set & Setting
The deliriant experience produced by supratherapeutic diphenhydramine is fundamentally unlike psychedelic or dissociative states. Set and setting provide minimal modulation — anticholinergic delirium is not steerable, and hallucinations are not recognized as such during the experience.
A sober companion is essential at any dose above the therapeutic range, as users routinely lose the ability to distinguish hallucination from reality, may attempt to leave the environment, or interact with objects and people who are not present. The environment should be physically safe: sharp objects removed, exterior doors secured.
Aftercare & integration. Physical recovery: Rehydrate — anticholinergic effects cause significant fluid loss through dry mucous membranes and impaired sweating. Eat when appetite returns; gastrointestinal slowdown may persist for 12–24 hours. Expect residual drowsiness, brain fog, and impaired short-term memory for 1–2 days following supratherapeutic doses.
Psychological processing: Hallucinations during anticholinergic delirium can be vivid, frightening, and difficult to distinguish from genuine memories even after the acute experience resolves. If intrusive memories, sleep disturbances, or persistent anxiety develop in the following days, consulting a mental health professional is appropriate. The experience carries no insight content — only confusion and fear.
Recovery & Support
Diphenhydramine dependence is documented and underrecognized.[2] Chronic users often escalate from therapeutic sleep-aid doses to hundreds of milligrams daily. Cessation after prolonged use produces rebound effect insomnia, anxiety, and irritability that drive relapse.
Daily use with dose escalation to maintain the same effect is a sign of dependence — a healthcare provider can help with tapering and safer alternatives. Cognitive behavioral therapy for insomnia (CBT-I) and non-anticholinergic medications are safer long-term options. SAMHSA's National Helpline (1-800-662-4357, US) and local poison control centers can provide guidance specific to diphenhydramine.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Uncomfortable but manageable: dry mouth, drowsiness, mild confusion. Seek immediate help if any of these appear: seizures, chest pain, rapid or irregular heartbeat, difficulty breathing, high fever, inability to urinate, complete disorientation, loss of consciousness, or self-harm behavior.
Immediate steps:
- 1. Call emergency services immediately if the person is having seizures, difficulty breathing, chest pain, or is unresponsive
- 2. Place the person in the recovery position if unconscious but breathing
- 3. Do not induce vomiting
- 4. Do not leave the person alone — they may hallucinate and act on what they perceive
- 5. Remove hazards from the environment: sharp objects, stairs access, exterior doors
What to tell the dispatcher:
State the substance (diphenhydramine/Benadryl), estimated amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Medical interventions:
Activated charcoal may be given if within 1 hour of ingestion. Sodium bicarbonate treats cardiac conduction abnormalities. Physostigmine reverses severe anticholinergic delirium when no contraindications exist. Benzodiazepines manage seizures.[3]
Legal Status[edit]
Diphenhydramine is not a controlled substance in any reviewed jurisdiction and is not scheduled under the United States Controlled Substances Act. Its regulatory status concerns over-the-counter availability, not controlled substance classification — and that status is actively changing as misuse-related adverse events accumulate.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | OTC (unscheduled) | Prescription from 1946; OTC 1982 (some formulations), 1985 (additional)[8][9] |
| United Kingdom | OTC | Available without prescription[9] |
| Canada | OTC | Available without prescription[9] |
| Australia | Schedule 4 (prescription-only) | Reclassified effective July 1, 2026, driven by rising ED presentations and misuse[11] |
| Germany | Prescription-only | Not available OTC[9] |
| Netherlands | Prescription-only | Not available OTC[9] |
| Sweden | Prescription-only | Not available OTC[9] |
Australia's rescheduling to prescription-only in 2026 represents a significant precedent for a compound with decades of OTC history. Other jurisdictions with current OTC status may follow as misuse data accumulate.
Legal status changes frequently and varies by jurisdiction. This information reflects available data as of the article's last update and is not legal advice.
references
- [1]
- [2] ^abcdErbe S, Bschor T (2013) [Diphenhydramine addiction and detoxification. A systematic review and case report]. — Psychiatrische Praxis doi:10.1055/s-0032-1332949
- [3]
- [4] ^abcMacorano E, Tarozzi I, Gitto L (2026) Death due to diphenhydramine toxicity: A 9-year review from the Cook County Medical Examiner's Office and a review of the literature. — Journal of Forensic Sciences doi:10.1111/1556-4029.70239
- [5] ^abCarroll S, McGee M, Audette M, Tuttle M, Corcoran J, Stanton M, Feldman R (2026) Lidocaine for diphenhydramine-induced ventricular tachycardia: A case report. — The American Journal of Emergency Medicine doi:10.1016/j.ajem.2026.01.040
- [6] ^abcZhu N, Eriksdotter M, Liabeuf S, Tan ECK, Johnell K, Garcia-Ptacek S, Xu H (2025) Anticholinergic burden and incident dementia: a Swedish nationwide case-control study. — Alzheimer's Research & Therapy doi:10.1186/s13195-025-01883-8